Sight Sciences (NASDAQ:SGHT) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Posted by Brian Himes on Aug 5th, 2026

Sight Sciences (NASDAQ:SGHT – Get Free Report) released its quarterly earnings results on Wednesday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.10, FiscalAI reports. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. The business had revenue of $23.39 million for the quarter, compared to analyst estimates of $21.72 million.

Here are the key takeaways from Sight Sciences’ conference call:

Positive Sentiment: Second-quarter revenue increased 20% year over year to $23.4 million, driven by growth in both interventional glaucoma and dry eye; net loss improved 63% to $4.4 million.
Positive Sentiment: Management raised 2026 revenue guidance to $88 million–$92 million and lowered adjusted operating expense guidance to $92 million–$94 million, citing stronger execution and continued expense discipline.
Positive Sentiment: TearCare dry-eye revenue nearly doubled sequentially to a record $2.7 million, with ordering accounts rising to 176 and covered lives increasing to approximately 14.5 million. The company expects reimbursement-related momentum to build in the second half, although additional payer wins are not included in guidance.
Positive Sentiment: OMNI glaucoma revenue grew 8% year over year, while active accounts reached a record and utilization recovered to its highest level since late 2024. Aetna added roughly 25 million covered lives, and the company plans a staged OMNI Ultra rollout beginning before its full launch at the AAO meeting and broader adoption in 2027.
Negative Sentiment: Cash declined to $79.8 million after a $5.4 million Alcon litigation-related success-fee payment; the company also faces ongoing legal uncertainty as Alcon appeals the judgment, which included approximately $55 million in damages and interest plus future royalties.

Sight Sciences Price Performance

Shares of SGHT traded down $0.09 during trading hours on Wednesday, hitting $5.55. 458,343 shares of the company were exchanged, compared to its average volume of 173,958. The company has a quick ratio of 5.48, a current ratio of 5.86 and a debt-to-equity ratio of 0.68. Sight Sciences has a fifty-two week low of $3.19 and a fifty-two week high of $9.24. The company has a market cap of $301.98 million, a price-to-earnings ratio of -7.82 and a beta of 2.38. The firm’s fifty day moving average is $5.14 and its 200 day moving average is $4.90.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Weiss Ratings cut Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 11th. Citigroup increased their target price on shares of Sight Sciences from $5.15 to $6.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Finally, UBS Group started coverage on Sight Sciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $7.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $7.75.

Check Out Our Latest Research Report on Sight Sciences

Insider Buying and Selling

In other news, CEO Paul Badawi sold 28,684 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.42, for a total value of $155,467.28. Following the transaction, the chief executive officer owned 6,122,472 shares in the company, valued at approximately $33,183,798.24. The trade was a 0.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeremy B. Hayden sold 12,733 shares of the business’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.51, for a total transaction of $70,158.83. Following the sale, the insider owned 357,037 shares of the company’s stock, valued at $1,967,273.87. This trade represents a 3.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 58,566 shares of company stock valued at $318,827. Company insiders own 30.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in shares of Sight Sciences by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after purchasing an additional 3,785 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Sight Sciences by 32.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Sight Sciences during the 2nd quarter valued at about $67,000. O Shaughnessy Asset Management LLC purchased a new position in shares of Sight Sciences during the fourth quarter valued at approximately $81,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Sight Sciences during the fourth quarter valued at approximately $96,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Key Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

Positive Sentiment: Q2 results exceeded expectations. Sight Sciences reported an adjusted loss of $0.08 per share, narrower than the $0.15–$0.18 analyst consensus and improved from a $0.23 loss a year earlier. Revenue rose to $23.39 million versus estimates of approximately $21.72 million. Sight Sciences Q2 earnings
Positive Sentiment: Full-year guidance was raised. The company now expects 2026 revenue of $88 million to $92 million, above the roughly $86.1 million consensus estimate, while also reducing its adjusted operating-expense outlook. Sight Sciences Q2 financial results
Positive Sentiment: Commercial access improved. Aetna updated its commercial glaucoma surgery policy to recognize the OMNI Surgical System and SION Surgical Instrument as medically necessary for eligible mild-to-moderate open-angle glaucoma patients, potentially expanding reimbursement and adoption. Aetna coverage announcement
Positive Sentiment: OMNI Ultra received FDA clearance. The next-generation implant-free glaucoma device enables single-pass circumferential canaloplasty followed by trabeculotomy and is scheduled for U.S. commercialization in the fourth quarter of 2026. OMNI Ultra FDA clearance
Negative Sentiment: Profitability remains a concern. SGHT continues to post net losses, with a negative net margin and return on equity, so investors may require evidence that stronger sales and lower expenses can lead to sustained profitability.
Negative Sentiment: Insider selling may weigh on sentiment. Reported insider activity over the past six months included 13 sales and no purchases, including sales by senior executives.

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.